Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00726_DB01149_nanopub.RAZ2j5tfT9Krom4QL3-bWYhi4BADxy_q2U23W293MepUw#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00726_DB01149 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00726_DB01149 label "DDI between Trimipramine and Nefazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed. [drugbank_resource:DB00726_DB01149]" assertion.
- drugbank_resource:DB00726_DB01149 identifier "drugbank_resource:DB00726_DB01149" assertion.
- drugbank_resource:DB00726_DB01149 title "DDI between Trimipramine and Nefazodone - Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed." assertion.
- drugbank:DB00726 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00726_DB01149 assertion.
- drugbank:DB01149 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00726_DB01149 assertion.